Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108355 · ClinicalTrials.gov registry record · Phase 4
Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis
A Phase 4 study of Cirrhosis and Ascites, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT00108355 is a Phase 4 study of Cirrhosis and Ascites that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 29 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00108355, a Phase 4 study of Cirrhosis and Ascites, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
Interventions
- DRUG Midodrine
- DRUG Octreotide LAR
- DRUG Albumin
- DRUG Intravenous Saline Infusion (Albumin placebo)
- DRUG Oral tablet (Midodrine placebo)
Study Locations (1)
Connecticut
- VA Connecticut Health Care System (West Haven) - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2003-12 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108355
The ClinicalTrials.gov registry entry for NCT00108355 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 5 interventions - of which Midodrine is the first listed.
NCT00108355 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00108355 about?
NCT00108355 is a clinical study titled "Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis". This clinical trial compares a combination of two drugs that constrict blood vessels (Octreotide LAR and Midodrine) to albumin after large volume paracentesis. Subjects have cirrhosis and ascites.
What is the current status of trial NCT00108355?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2003-12. Estimated completion is 2012-08.
What conditions does trial NCT00108355 study?
This clinical trial studies the following conditions: Cirrhosis, Ascites.
What interventions are being tested in trial NCT00108355?
The interventions under investigation include: Midodrine (DRUG), Octreotide LAR (DRUG), Albumin (DRUG), Intravenous Saline Infusion (Albumin placebo) (DRUG), Oral tablet (Midodrine placebo) (DRUG).
Who is sponsoring clinical trial NCT00108355?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00108355 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ramelteon for Treatment of Insomnia in Cirrhosis
COMPLETED · Phase 4
-
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
COMPLETED · Phase 4
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.